Centrus Reports Fourth Quarter and Full Year 2025 Results and Provides 2026 Guidance
- 2025 full year revenue of
$448.7 million and gross profit of$117.5 million , compared to prior year revenue of$442.0 million and gross profit of$111.5 million - 2025 full year net income of
$77.8 million , compared to prior year net income of$73.2 million - Strengthened balance sheet and increased unrestricted cash balance to
$2.0 billion - Enriched over 1 metric ton of high-assay low-enriched uranium ("HALEU") UF6
- Selected by the
U.S. Department of Energy ("DOE ") for a$900.0 million HALEU production award, subject to negotiation - Notified by
National Nuclear Security Administration ("NNSA") of its intent to sole source certain uranium enrichment activities fromCentrus - Launched domestic commercial centrifuge manufacturing to support substantial
$2.3 billion commercial low enriched uranium ("LEU") backlog - Activities to support current LEU backlog and proposed 12 metric tons of HALEU production expected to be sufficient to reach nth-of-a-kind cost
"2025 was a milestone year for
"The LEU pricing curve's sharp rise continues to demonstrate that there is a clear need for additional enrichment capacity for growing electrification demands.
Full Year Financial Results
Revenue from the LEU segment was
Revenue from the Technical Solutions segment was
Cost of sales for the LEU segment was
Cost of sales for the Technical Solutions segment was
The Company recognized a gross profit of
Gross profit for the LEU segment was
Gross profit for the Technical Solutions segment was
Expansion of Manufacturing and Enrichment Capacity Update
On
In
Backlog
The Company's total backlog is
2026 Outlook
The company is providing certain financial and operational guidance for the full-year 2026.
Financial 2026 Outlook
For the full year 2026, on a consolidated basis,
- Total revenue to be in the range of
$425 million to$475 million - Total capital deployment to be in the range of
$350 million to$500 million , driven by increased investment in the Company's industrial build out related to its centrifuge manufacturing
Operational 2026 Outlook
For the full year 2026, on a consolidated basis,
- Finalize contracts with all partners identified as critical to its industrial build out
- At least 100 net new employee hires for
Oak Ridge, Tennessee , facility - At least 50 net new employee hires for
Piketon, Ohio , facility - Release of a Certified for Construction package
The Company's 2026 guidance is subject to a number of assumptions and uncertainties that could affect results either positively or negatively. Variations from these expectations could cause differences between this guidance and the ultimate results. This includes the assumption of no significant change in restrictions in our ability to receive and sell Russian LEU or other uranium products, no significant economic disruptions or downturns, the successful implementation of our planned expansion projects, including the finalization and funding of the
About
With world-class technical and engineering capabilities,
Forward-Looking Statements:
This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "will", "should", "could", "would" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions with respect to future events and operational, economic and financial performance. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may be exacerbated by any worsening of the global business and economic environment, including but not limited to, risks and uncertainties related to the following:
- the war in
Ukraine and other geopolitical conflicts, including the resulting bans, laws, tariffs, sanctions or other government measures, and actions by third parties, including contractual counterparties, as a result of such conflicts that could directly or indirectly impact our ability to obtain, deliver, transport, sell or collect payment for, LEU or the SWU and natural uranium hexafluoride components of LEU; - our reliance on third party suppliers to provide essential products and services to us;
- restrictions on imports and exports, including those imposed under the RSA, and related international trade legislation;
- our government contracts, including related to government shutdowns, changes to the
U.S. government's appropriated funding levels for HALEU and the government's inability to satisfy its obligations, and our lease to our facility inPiketon, Ohio ; - our receipt of additional task orders under the HALEU Production Contract, LEU Production Contract and HALEU Deconversion Contract and, if awarded, the nature, timing and amount thereof;
- our ability to obtain new contracts or funding to be able to continue operations;
- whether or when government demand for HALEU or LEU for government or commercial uses will materialize and at what level;
- the impact and potential extended duration of a supply/demand imbalance in the market for LEU;
- significant competition from major LEU producers, including foreign competitors, who may be less cost sensitive than we are;
- limitations on our ability to compete in foreign markets;
- pricing trends and demand in the uranium and enrichment markets, especially in light of the potential of limited supply and our dependence on others for deliveries of LEU;
- our ability to successfully implement our planned expansion projects in
Piketon, Ohio andOak Ridge, Tennessee ; - natural and other disasters;
- pandemics and other health crises;
- the fact that our revenue is largely dependent on our largest customers and our sales backlog;
- our long-term liabilities, including our postretirement health and life benefit obligations, our 0% Convertible Notes and our 2.25% Convertible Notes;
- failures or security, including cybersecurity, breaches of our information technology systems; and
- the impact of, or changes to, government regulation and policies or interpretation of laws or regulations, including by the
SEC ,DOE , DOC and the NRC.
Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this news release and in our filings with the
Contacts:
Investors:
Media:
|
|
|||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||
|
|
2025 |
|
2024 |
|
2023 |
|
2025 |
|
2024 |
|
2023 |
|
Numerator (in millions): |
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
$ 17.8 |
|
$ 53.7 |
|
$ 56.3 |
|
$ 77.8 |
|
$ 73.2 |
|
$ 84.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator (in thousands): |
|
|
|
|
|
|
|
|
|
|
|
|
Average common shares outstanding - basic |
18,844 |
|
16,716 |
|
15,461 |
|
17,967 |
|
16,309 |
|
15,212 |
|
Potentially dilutive shares related to equity- |
48 |
|
62 |
|
271 |
|
58 |
|
64 |
|
289 |
|
Potentially dilutive shares related to 2.25% |
2,795 |
|
— |
|
— |
|
1,900 |
|
— |
|
— |
|
Potentially dilutive shares related to 0% |
840 |
|
— |
|
— |
|
— |
|
— |
|
— |
|
Average common shares outstanding - diluted |
22,527 |
|
16,778 |
|
15,732 |
|
19,925 |
|
16,373 |
|
15,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share (in dollars): |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ 0.94 |
|
$ 3.21 |
|
$ 3.64 |
|
$ 4.33 |
|
$ 4.49 |
|
$ 5.55 |
|
Diluted |
$ 0.79 |
|
$ 3.20 |
|
$ 3.58 |
|
$ 3.90 |
|
$ 4.47 |
|
$ 5.44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0% Convertible Notes (if-converted) excluded from |
— |
|
— |
|
— |
|
951 |
|
— |
|
— |
|
|
|||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||
|
|
2025 |
|
2024 |
|
2023 |
|
2025 |
|
2024 |
|
2023 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Separative work units |
$ 111.0 |
|
$ 48.7 |
|
$ 60.8 |
|
$ 298.7 |
|
$ 246.8 |
|
$ 208.2 |
|
Uranium |
13.4 |
|
73.2 |
|
21.3 |
|
47.5 |
|
103.1 |
|
60.8 |
|
Technical solutions |
21.8 |
|
29.7 |
|
21.5 |
|
102.5 |
|
92.1 |
|
51.2 |
|
Total revenue |
146.2 |
|
151.6 |
|
103.6 |
|
448.7 |
|
442.0 |
|
320.2 |
|
Cost of Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Separative work units and uranium |
87.0 |
|
66.7 |
|
37.8 |
|
234.7 |
|
256.0 |
|
163.9 |
|
Technical solutions |
24.2 |
|
23.1 |
|
16.0 |
|
96.5 |
|
74.5 |
|
44.2 |
|
Total cost of sales |
111.2 |
|
89.8 |
|
53.8 |
|
331.2 |
|
330.5 |
|
208.1 |
|
Gross profit |
35.0 |
|
61.8 |
|
49.8 |
|
117.5 |
|
111.5 |
|
112.1 |
|
Advanced technology costs |
8.9 |
|
3.3 |
|
3.4 |
|
16.9 |
|
17.2 |
|
14.2 |
|
Selling, general and administrative |
10.3 |
|
10.4 |
|
11.4 |
|
36.2 |
|
35.0 |
|
36.9 |
|
Equity-related compensation |
0.5 |
|
0.4 |
|
0.3 |
|
5.8 |
|
1.5 |
|
2.3 |
|
Amortization of intangible assets |
2.5 |
|
2.6 |
|
2.1 |
|
8.4 |
|
9.8 |
|
6.3 |
|
Operating income |
12.8 |
|
45.1 |
|
32.6 |
|
50.2 |
|
48.0 |
|
52.4 |
|
Nonoperating components of net |
3.9 |
|
0.7 |
|
(23.3) |
|
6.8 |
|
(14.7) |
|
(23.2) |
|
Interest expense |
4.1 |
|
1.9 |
|
0.4 |
|
14.0 |
|
2.7 |
|
1.3 |
|
Investment income |
(16.5) |
|
(5.1) |
|
(2.3) |
|
(44.7) |
|
(12.9) |
|
(8.7) |
|
Extinguishment of long-term debt |
— |
|
— |
|
— |
|
(11.8) |
|
— |
|
— |
|
Other income, net |
— |
|
(0.2) |
|
(0.5) |
|
— |
|
(0.1) |
|
(1.5) |
|
Income before income taxes |
21.3 |
|
47.8 |
|
58.3 |
|
85.9 |
|
73.0 |
|
84.5 |
|
Income tax expense (benefit) |
3.5 |
|
(5.9) |
|
2.0 |
|
8.1 |
|
(0.2) |
|
0.1 |
|
Net income and comprehensive income |
17.8 |
|
53.7 |
|
56.3 |
|
77.8 |
|
73.2 |
|
84.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ 0.94 |
|
$ 3.21 |
|
$ 3.64 |
|
$ 4.33 |
|
$ 4.49 |
|
$ 5.55 |
|
Diluted |
$ 0.79 |
|
$ 3.20 |
|
$ 3.58 |
|
$ 3.90 |
|
$ 4.47 |
|
$ 5.44 |
|
Average number of common shares |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
18,844 |
|
16,716 |
|
15,461 |
|
17,967 |
|
16,309 |
|
15,212 |
|
Diluted |
22,527 |
|
16,778 |
|
15,732 |
|
19,925 |
|
16,373 |
|
15,501 |
|
|
|||||
|
|
Year Ended |
||||
|
|
2025 |
|
2024 |
|
2023 |
|
OPERATING |
|
|
|
|
|
|
Net income |
$ 77.8 |
|
$ 73.2 |
|
$ 84.4 |
|
Adjustments to reconcile net income to cash provided by operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
9.9 |
|
10.8 |
|
7.1 |
|
Accrued loss on long-term contract |
— |
|
— |
|
(20.0) |
|
Deferred tax assets |
7.4 |
|
(0.7) |
|
(1.6) |
|
Loss (gain) on remeasurement of retirement benefit plans, net |
2.9 |
|
(17.3) |
|
(24.6) |
|
Revaluation of inventory borrowing |
3.6 |
|
2.1 |
|
7.4 |
|
Gain on extinguishment of 8.25% Notes |
(11.8) |
|
— |
|
— |
|
Equity-related compensation |
5.8 |
|
1.5 |
|
2.3 |
|
Amortization of debt issuance costs and discount |
3.4 |
|
0.3 |
|
— |
|
Other reconciling adjustments, net |
0.1 |
|
(0.2) |
|
(1.6) |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
49.2 |
|
(30.5) |
|
(11.3) |
|
Inventories |
(230.0) |
|
101.0 |
|
(83.8) |
|
Inventories owed to customers and suppliers |
176.5 |
|
(68.1) |
|
23.5 |
|
Other current assets |
2.2 |
|
2.4 |
|
14.9 |
|
Payables under inventory purchase agreements |
(11.0) |
|
(12.4) |
|
(1.7) |
|
Deferred revenue and advances from customers, net of deferred costs |
(29.5) |
|
(15.1) |
|
12.1 |
|
Accounts payable and other liabilities |
0.4 |
|
(1.4) |
|
8.5 |
|
Pension and postretirement liabilities |
(5.7) |
|
(8.3) |
|
(5.7) |
|
Other changes, net |
(0.2) |
|
(0.3) |
|
(0.8) |
|
Cash provided by operating activities |
51.0 |
|
37.0 |
|
9.1 |
|
|
|
|
|
|
|
|
INVESTING |
|
|
|
|
|
|
Capital expenditures |
(19.7) |
|
(4.1) |
|
(1.6) |
|
Cash used in investing activities |
(19.7) |
|
(4.1) |
|
(1.6) |
|
|
|
|
|
|
|
|
FINANCING |
|
|
|
|
|
|
Proceeds from the issuance of common stock, net |
523.7 |
|
54.7 |
|
23.2 |
|
Proceeds from the issuance of 0% and 2.25% Convertible Senior Notes, net |
782.4 |
|
388.7 |
|
— |
|
Payment of interest classified as debt |
(3.5) |
|
(6.1) |
|
(6.1) |
|
Payment of principal to redeem 8.25% Notes |
(74.3) |
|
— |
|
— |
|
Exercise of stock options |
— |
|
0.4 |
|
— |
|
Common stock withheld for tax obligations under equity-related compensation plan |
(3.4) |
|
(0.6) |
|
(3.0) |
|
Other |
— |
|
— |
|
(0.2) |
|
Cash provided by financing activities |
1,224.9 |
|
437.1 |
|
13.9 |
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
(0.1) |
|
0.2 |
|
— |
|
|
|
|
|
|
|
|
Increase in cash, cash equivalents and restricted cash |
1,256.1 |
|
470.2 |
|
21.4 |
|
Cash, cash equivalents and restricted cash, beginning of period |
704.0 |
|
233.8 |
|
212.4 |
|
Cash, cash equivalents and restricted cash, end of period |
$ 1,960.1 |
|
$ 704.0 |
|
$ 233.8 |
|
|
|||||
|
|
Year Ended |
||||
|
|
2025 |
|
2024 |
|
2023 |
|
Supplemental cash flow information: |
|
|
|
|
|
|
Cash paid for interest |
$ 8.9 |
|
$ — |
|
$ — |
|
Cash paid for income taxes |
|
|
|
|
|
|
Federal |
$ — |
|
$ — |
|
$ — |
|
State |
$ 0.7 |
|
$ 0.7 |
|
$ — |
|
Foreign |
$ — |
|
$ — |
|
$ — |
|
|
|
|
|
|
|
|
Cash paid for income taxes (net of refunds received) exceeding five percent of total cash paid |
|
|
|
|
|
|
State: |
|
|
|
|
|
|
|
$ 0.7 |
|
$ 0.5 |
|
$ — |
|
|
$ — |
|
$ 0.2 |
|
$ — |
|
Total |
$ 0.7 |
|
$ 0.7 |
|
$ — |
|
|
|
|
|
|
|
|
Non-cash activities: |
|
|
|
|
|
|
Property, plant and equipment included in accounts payable and accrued liabilities |
$ 2.0 |
|
$ 0.2 |
|
$ 0.9 |
|
Equity-related transaction costs included in accounts payable and accrued liabilities |
$ 0.2 |
|
$ — |
|
$ — |
|
Adjustment to right to use lease assets from lease modification |
$ 1.3 |
|
$ — |
|
$ (4.2) |
|
|
|||
|
|
|
||
|
|
2025 |
|
2024 |
|
ASSETS |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
$ 1,957.2 |
|
$ 671.4 |
|
Accounts receivable |
30.7 |
|
80.0 |
|
Inventories |
322.9 |
|
161.6 |
|
Deferred costs associated with deferred revenue |
40.9 |
|
63.9 |
|
Other current assets |
11.9 |
|
38.3 |
|
Total current assets |
2,363.6 |
|
1,015.2 |
|
Property, plant and equipment, net |
29.5 |
|
9.4 |
|
Deposits for financial assurance |
2.7 |
|
2.6 |
|
Intangible assets, net |
21.2 |
|
29.6 |
|
Deferred tax assets, net |
21.9 |
|
29.3 |
|
Other long-term assets |
7.0 |
|
7.3 |
|
Total assets |
$ 2,445.9 |
|
$ 1,093.4 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable and accrued liabilities |
$ 41.6 |
|
$ 38.8 |
|
Payables under inventory purchase agreements |
18.5 |
|
29.5 |
|
Inventories owed to customers and suppliers |
192.7 |
|
16.2 |
|
Deferred revenue and advances from customers |
131.1 |
|
216.4 |
|
Short-term inventory loans |
38.9 |
|
39.8 |
|
Current debt |
— |
|
6.1 |
|
Total current liabilities |
422.8 |
|
346.8 |
|
Long-term debt |
1,174.8 |
|
472.5 |
|
Postretirement health and life benefit obligations |
72.2 |
|
74.6 |
|
Pension benefit liabilities |
3.0 |
|
4.0 |
|
Long-term inventory loans |
— |
|
26.2 |
|
Other long-term liabilities |
8.0 |
|
7.9 |
|
Total liabilities |
1,680.8 |
|
932.0 |
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
Preferred stock, par value |
|
|
|
|
Series A Participating Cumulative Preferred Stock, none issued |
— |
|
— |
|
Series B Senior Preferred Stock, none issued |
— |
|
— |
|
Class A Common Stock, par value |
1.9 |
|
1.6 |
|
Class B Common Stock, par value |
0.1 |
|
0.1 |
|
Excess of capital over par value |
762.3 |
|
236.5 |
|
Retained earnings (accumulated deficit) |
1.5 |
|
(76.3) |
|
Accumulated other comprehensive loss |
(0.7) |
|
(0.5) |
|
Total stockholders' equity |
765.1 |
|
161.4 |
|
Total liabilities and stockholders' equity |
$ 2,445.9 |
|
$ 1,093.4 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/centrus-reports-fourth-quarter-and-full-year-2025-results-and-provides-2026-guidance-302684342.html
SOURCE